- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
Patent holdings for IPC class A61K 31/41
Total number of patents in this class: 2800
10-year publication summary
|
151
|
171
|
153
|
157
|
140
|
146
|
139
|
127
|
121
|
85
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10721 |
80 |
| SK Biopharmaceuticals Co., Ltd. | 262 |
73 |
| Merck Sharp & Dohme Corp. | 2190 |
44 |
| Bristol-myers Squibb Company | 4849 |
38 |
| Merck Sharp & Dohme LLC | 3753 |
34 |
| Allergan, Inc. | 2337 |
33 |
| The Regents of the University of California | 20108 |
24 |
| Boehringer Ingelheim International GmbH | 4640 |
23 |
| F. Hoffmann-La Roche AG | 7948 |
22 |
| Scandion Oncology A/S | 28 |
19 |
| Shenzhen Salubris Pharmaceuticals Co., Ltd | 96 |
16 |
| AstraZeneca AB | 2886 |
15 |
| Centre National de La Recherche Scientifique | 10564 |
15 |
| Bayer Pharma AG | 1054 |
15 |
| The Johns Hopkins University | 5714 |
15 |
| The General Hospital Corporation | 4770 |
14 |
| Boryung Pharmaceutical Co., Ltd. | 63 |
14 |
| Theravance Biopharma R&D IP, LLC | 456 |
14 |
| Rigel Pharmaceuticals, Inc. | 538 |
13 |
| Genentech, Inc. | 4009 |
12 |
| Other owners | 2267 |